Koninklijke Philips N.V.
Koninklijke Philips N.V. (PHIA.AS) Stock Competitors & Peer Comparison
See (PHIA.AS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PHIA.AS | €22.84 | -1.13% | 21.7B | 142.75 | €0.16 | +3.72% |
| IBAB.BR | €11.68 | -3.79% | 342.2M | 37.68 | €0.31 | +2.05% |
| EAPI.PA | €2.79 | -3.12% | 265.5M | -2.02 | -€1.38 | N/A |
| ALERS.PA | €25.40 | +0.00% | 254.9M | 65.13 | €0.39 | N/A |
| GBT.PA | €20.20 | -3.81% | 254.6M | 15.91 | €1.27 | N/A |
| ALCOR.PA | €35.10 | +0.29% | 154.5M | -234.00 | -€0.15 | N/A |
| SEQUA.BR | €1.38 | +1.47% | 80.5M | -1.13 | -€1.22 | N/A |
| AFME.PA | €1.32 | -0.38% | 51.8M | -3.22 | -€0.41 | N/A |
| ALMDT.PA | €1.91 | -24.95% | 38M | -1.19 | -€1.61 | N/A |
| ALNOV.PA | €0.46 | -0.98% | 32.2M | -0.71 | -€0.64 | N/A |
Stock Comparison
PHIA.AS vs IBAB.BR Comparison August 2025
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 21.7B. In comparison, IBAB.BR has a market cap of 342.2M. Regarding current trading prices, PHIA.AS is priced at €22.84, while IBAB.BR trades at €11.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 142.75, whereas IBAB.BR's P/E ratio is 37.68. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to IBAB.BR's ROE of +0.09%. Regarding short-term risk, PHIA.AS is less volatile compared to IBAB.BR. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check IBAB.BR's competition here
PHIA.AS vs EAPI.PA Comparison August 2025
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 21.7B. In comparison, EAPI.PA has a market cap of 265.5M. Regarding current trading prices, PHIA.AS is priced at €22.84, while EAPI.PA trades at €2.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 142.75, whereas EAPI.PA's P/E ratio is -2.02. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to EAPI.PA's ROE of -0.14%. Regarding short-term risk, PHIA.AS is less volatile compared to EAPI.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check EAPI.PA's competition here
PHIA.AS vs ALERS.PA Comparison August 2025
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 21.7B. In comparison, ALERS.PA has a market cap of 254.9M. Regarding current trading prices, PHIA.AS is priced at €22.84, while ALERS.PA trades at €25.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 142.75, whereas ALERS.PA's P/E ratio is 65.13. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to ALERS.PA's ROE of +0.02%. Regarding short-term risk, PHIA.AS is more volatile compared to ALERS.PA. This indicates potentially higher risk in terms of short-term price fluctuations for PHIA.AS.Check ALERS.PA's competition here
PHIA.AS vs GBT.PA Comparison August 2025
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 21.7B. In comparison, GBT.PA has a market cap of 254.6M. Regarding current trading prices, PHIA.AS is priced at €22.84, while GBT.PA trades at €20.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 142.75, whereas GBT.PA's P/E ratio is 15.91. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to GBT.PA's ROE of +0.04%. Regarding short-term risk, PHIA.AS is less volatile compared to GBT.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check GBT.PA's competition here
PHIA.AS vs ALCOR.PA Comparison August 2025
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 21.7B. In comparison, ALCOR.PA has a market cap of 154.5M. Regarding current trading prices, PHIA.AS is priced at €22.84, while ALCOR.PA trades at €35.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 142.75, whereas ALCOR.PA's P/E ratio is -234.00. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to ALCOR.PA's ROE of -0.23%. Regarding short-term risk, PHIA.AS is more volatile compared to ALCOR.PA. This indicates potentially higher risk in terms of short-term price fluctuations for PHIA.AS.Check ALCOR.PA's competition here
PHIA.AS vs SEQUA.BR Comparison August 2025
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 21.7B. In comparison, SEQUA.BR has a market cap of 80.5M. Regarding current trading prices, PHIA.AS is priced at €22.84, while SEQUA.BR trades at €1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 142.75, whereas SEQUA.BR's P/E ratio is -1.13. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to SEQUA.BR's ROE of +2.05%. Regarding short-term risk, PHIA.AS is less volatile compared to SEQUA.BR. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check SEQUA.BR's competition here
PHIA.AS vs AFME.PA Comparison August 2025
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 21.7B. In comparison, AFME.PA has a market cap of 51.8M. Regarding current trading prices, PHIA.AS is priced at €22.84, while AFME.PA trades at €1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 142.75, whereas AFME.PA's P/E ratio is -3.22. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to AFME.PA's ROE of -0.51%. Regarding short-term risk, PHIA.AS is less volatile compared to AFME.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check AFME.PA's competition here
PHIA.AS vs ALMDT.PA Comparison August 2025
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 21.7B. In comparison, ALMDT.PA has a market cap of 38M. Regarding current trading prices, PHIA.AS is priced at €22.84, while ALMDT.PA trades at €1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 142.75, whereas ALMDT.PA's P/E ratio is -1.19. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to ALMDT.PA's ROE of +0.90%. Regarding short-term risk, PHIA.AS is less volatile compared to ALMDT.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check ALMDT.PA's competition here
PHIA.AS vs ALNOV.PA Comparison August 2025
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 21.7B. In comparison, ALNOV.PA has a market cap of 32.2M. Regarding current trading prices, PHIA.AS is priced at €22.84, while ALNOV.PA trades at €0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 142.75, whereas ALNOV.PA's P/E ratio is -0.71. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to ALNOV.PA's ROE of +0.00%. Regarding short-term risk, PHIA.AS is less volatile compared to ALNOV.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check ALNOV.PA's competition here
PHIA.AS vs MKEA.PA Comparison August 2025
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 21.7B. In comparison, MKEA.PA has a market cap of 30.2M. Regarding current trading prices, PHIA.AS is priced at €22.84, while MKEA.PA trades at €0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 142.75, whereas MKEA.PA's P/E ratio is -2.49. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to MKEA.PA's ROE of +0.74%. Regarding short-term risk, PHIA.AS is more volatile compared to MKEA.PA. This indicates potentially higher risk in terms of short-term price fluctuations for PHIA.AS.Check MKEA.PA's competition here
PHIA.AS vs ALDMS.PA Comparison August 2025
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 21.7B. In comparison, ALDMS.PA has a market cap of 27.9M. Regarding current trading prices, PHIA.AS is priced at €22.84, while ALDMS.PA trades at €1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 142.75, whereas ALDMS.PA's P/E ratio is -10.73. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to ALDMS.PA's ROE of -0.25%. Regarding short-term risk, PHIA.AS is less volatile compared to ALDMS.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check ALDMS.PA's competition here
PHIA.AS vs ALTHE.PA Comparison August 2025
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 21.7B. In comparison, ALTHE.PA has a market cap of 24.5M. Regarding current trading prices, PHIA.AS is priced at €22.84, while ALTHE.PA trades at €0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 142.75, whereas ALTHE.PA's P/E ratio is -5.87. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to ALTHE.PA's ROE of -1.29%. Regarding short-term risk, PHIA.AS is less volatile compared to ALTHE.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check ALTHE.PA's competition here
PHIA.AS vs ALCAR.PA Comparison August 2025
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 21.7B. In comparison, ALCAR.PA has a market cap of 21.8M. Regarding current trading prices, PHIA.AS is priced at €22.84, while ALCAR.PA trades at €0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 142.75, whereas ALCAR.PA's P/E ratio is -0.31. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to ALCAR.PA's ROE of +1.40%. Regarding short-term risk, PHIA.AS is less volatile compared to ALCAR.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check ALCAR.PA's competition here
PHIA.AS vs ALIKO.PA Comparison August 2025
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 21.7B. In comparison, ALIKO.PA has a market cap of 21.2M. Regarding current trading prices, PHIA.AS is priced at €22.84, while ALIKO.PA trades at €1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 142.75, whereas ALIKO.PA's P/E ratio is -5.85. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to ALIKO.PA's ROE of -0.17%. Regarding short-term risk, PHIA.AS is less volatile compared to ALIKO.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check ALIKO.PA's competition here
PHIA.AS vs ALIMP.PA Comparison August 2025
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 21.7B. In comparison, ALIMP.PA has a market cap of 20.8M. Regarding current trading prices, PHIA.AS is priced at €22.84, while ALIMP.PA trades at €0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 142.75, whereas ALIMP.PA's P/E ratio is -4.16. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to ALIMP.PA's ROE of -2.06%. Regarding short-term risk, PHIA.AS is less volatile compared to ALIMP.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check ALIMP.PA's competition here
PHIA.AS vs ALTER.PA Comparison August 2025
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 21.7B. In comparison, ALTER.PA has a market cap of 17.3M. Regarding current trading prices, PHIA.AS is priced at €22.84, while ALTER.PA trades at €1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 142.75, whereas ALTER.PA's P/E ratio is 42.00. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to ALTER.PA's ROE of -0.06%. Regarding short-term risk, PHIA.AS is less volatile compared to ALTER.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check ALTER.PA's competition here
PHIA.AS vs ALEMG.PA Comparison August 2025
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 21.7B. In comparison, ALEMG.PA has a market cap of 12.4M. Regarding current trading prices, PHIA.AS is priced at €22.84, while ALEMG.PA trades at €4.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 142.75, whereas ALEMG.PA's P/E ratio is 29.13. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to ALEMG.PA's ROE of +0.94%. Regarding short-term risk, PHIA.AS is more volatile compared to ALEMG.PA. This indicates potentially higher risk in terms of short-term price fluctuations for PHIA.AS.Check ALEMG.PA's competition here
PHIA.AS vs ALBLU.PA Comparison August 2025
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 21.7B. In comparison, ALBLU.PA has a market cap of 11.2M. Regarding current trading prices, PHIA.AS is priced at €22.84, while ALBLU.PA trades at €0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 142.75, whereas ALBLU.PA's P/E ratio is -6.10. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to ALBLU.PA's ROE of -0.61%. Regarding short-term risk, PHIA.AS is more volatile compared to ALBLU.PA. This indicates potentially higher risk in terms of short-term price fluctuations for PHIA.AS.Check ALBLU.PA's competition here
PHIA.AS vs ALSGD.PA Comparison August 2025
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 21.7B. In comparison, ALSGD.PA has a market cap of 5.2M. Regarding current trading prices, PHIA.AS is priced at €22.84, while ALSGD.PA trades at €0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 142.75, whereas ALSGD.PA's P/E ratio is -1.38. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to ALSGD.PA's ROE of -0.59%. Regarding short-term risk, PHIA.AS is less volatile compared to ALSGD.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check ALSGD.PA's competition here
PHIA.AS vs DGM.PA Comparison August 2025
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 21.7B. In comparison, DGM.PA has a market cap of 0. Regarding current trading prices, PHIA.AS is priced at €22.84, while DGM.PA trades at €1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 142.75, whereas DGM.PA's P/E ratio is -4.43. In terms of profitability, PHIA.AS's ROE is +0.03%, compared to DGM.PA's ROE of -0.35%. Regarding short-term risk, PHIA.AS is less volatile compared to DGM.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check DGM.PA's competition here